Premium
Juvenile myoclonic epilepsy: diagnosis, management and outcome
Author(s) -
Sharpe Christine,
Buchanan Neil
Publication year - 1995
Publication title -
medical journal of australia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 131
eISSN - 1326-5377
pISSN - 0025-729X
DOI - 10.5694/j.1326-5377.1995.tb138476.x
Subject(s) - juvenile myoclonic epilepsy , lamotrigine , epilepsy , myoclonus , medicine , valproic acid , pediatrics , referral , anesthesia , psychiatry , family medicine
Objectives To study delay in diagnosis, seizure control, seizure‐pro‐voking factors, suitable medications and drug side effects in patients with juvenile myoclonic epilepsy. Design Telephone and personal interview of patients and review of their clinical notes. Participants and setting Thirty‐six patients attending an epilepsy clinic at a tertiary referral hospital. Results There was a substantial delay in the diagnosis of juvenile myoclonic epilepsy because the symptom of early‐morning myoclonus was not specifically sought. Sodium valproate is the drug of choice, producing absolute seizure control in 63% of cases (19/30). Most patients with poor seizure control had provoked seizures only, emphasising the importance of lifestyle in management. Half of the patients taking sodium valproate experienced side effects, such as weight gain. Lamotrigine is the most suitable alternative. Conclusions Juvenile myoclonic epilepsy is a common, under‐recognised form of epilepsy which is best treated with sodium valproate. If side effects occur, lamotrigine should be used.